Latest Articles

Publication Date
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Aprea reports second partial response in endometrial cancer trial - Investing.com

Aprea reports second partial response in endometrial cancer trial Investing.com

Published: Feb. 18, 2026, 1:42 p.m.
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - European Medical Journal

GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk European Medical Journal

Published: Feb. 18, 2026, noon
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - EMJ | Elevating the quality of healthcare globally

GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk EMJ | Elevating the quality of healthcare globally

Published: Feb. 18, 2026, noon
A 60-Year-Old Woman With Endometrial Intraepithelial Neoplasia: A Case of Persistent Postmenopausal Bleeding - Cureus

A 60-Year-Old Woman With Endometrial Intraepithelial Neoplasia: A Case of Persistent Postmenopausal Bleeding Cureus

Published: Feb. 18, 2026, 2:58 a.m.
Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair.

Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, …

Published: Feb. 18, 2026, midnight
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... - Medical Dialogues

Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... Medical Dialogues

Published: Feb. 17, 2026, 3:15 p.m.
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine

Published: Feb. 17, 2026, 12:15 a.m.
The letrozole use in reproductive medicine: Beyond aromatase inhibition - a comprehensive review.

Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By …

Published: Feb. 17, 2026, midnight
Metabolomics Analysis Reveals Gut Microbiota-Associated Sakuranin Modulates Endometrial Stem Cell Differentiation and Inflammation to Alleviate Pain in Endometriosis.

Endometriosis (EMS) is characterized by pain symptoms that seriously affect patients' quality of life. Gut microbiome-related metabolites (GMRM) play an important role in the process of EMS. However, the role …

Published: Feb. 17, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!